Lazard Asset Management LLC Purchases 3,881 Shares of Meridian Bioscience, Inc. (NASDAQ:VIVO)

Lazard Asset Management LLC boosted its stake in shares of Meridian Bioscience, Inc. (NASDAQ:VIVOGet Rating) by 13,860.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,909 shares of the company’s stock after purchasing an additional 3,881 shares during the quarter. Lazard Asset Management LLC’s holdings in Meridian Bioscience were worth $118,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of VIVO. Prospera Financial Services Inc acquired a new position in Meridian Bioscience during the 1st quarter valued at $42,000. Venture Visionary Partners LLC acquired a new position in Meridian Bioscience during the 2nd quarter valued at $64,000. KBC Group NV acquired a new position in Meridian Bioscience during the 2nd quarter valued at $113,000. First Bank & Trust raised its stake in Meridian Bioscience by 57.6% during the 2nd quarter. First Bank & Trust now owns 5,231 shares of the company’s stock valued at $159,000 after purchasing an additional 1,912 shares during the last quarter. Finally, Captrust Financial Advisors raised its stake in Meridian Bioscience by 23.8% during the 1st quarter. Captrust Financial Advisors now owns 7,782 shares of the company’s stock valued at $202,000 after purchasing an additional 1,495 shares during the last quarter. 93.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday.

Meridian Bioscience Trading Down 0.7 %

Shares of VIVO stock opened at $31.77 on Wednesday. Meridian Bioscience, Inc. has a 52-week low of $17.20 and a 52-week high of $34.38. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of 32.09 and a beta of 0.28. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.36 and a current ratio of 3.52. The firm has a fifty day moving average of $31.99 and a 200-day moving average of $30.87.

Meridian Bioscience Company Profile

(Get Rating)

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.

Further Reading

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVOGet Rating).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.